Literature DB >> 32247204

The impact of Coronavirus (COVID-19) on head and neck cancer patients' care.

Francesca De Felice1, Antonella Polimeni2, Vincenzo Tombolini3.   

Abstract

Entities:  

Keywords:  COVID-19; Care; Chemotherapy; Coronavirus; Head neck cancer; Radiotherapy; Surgery; Treatment

Year:  2020        PMID: 32247204      PMCID: PMC7138158          DOI: 10.1016/j.radonc.2020.03.020

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


× No keyword cloud information.
To monitor and defeat further progression of the novel Coronavirus (COVID-19) infection, a strong public health vigilance has been adopted in Italy [1]. By March 18, 31,772 cases were confirmed, with 2390 deaths [2]. The median age of patients who are infected is 63 years and more than two-thirds of deaths have occurred in elderly patients (aged ≥70 years) [2]. Hospitals’ work regimes have been re-prioritized, but Coronavirus does not really affect the cancer clinics. Although radiation oncologists are not fighting on the front line, they have to guarantee treatment – radiotherapy with or without concomitant chemotherapy ((C)RT) – and, in the meantime, protect patients from the COVID-19 infection. In this scenario, (C)RT has a crucial role in head and neck cancer (HNC) management. It is the mainstay of treatment for most of the HNC sites, because of its proven curative intent assuring an organ preservation strategy [3], [4]. HNC is a relatively rare cancer in Italy, with 9300 new cases and 3216 deaths described per year [5]. Most of the patients are diagnosed in a locally advanced stage disease and should receive treatment as soon as possible. Therefore, during this pandemic period, HNC patients represent a major clinical problem with treatment decision-making process. Due to the complexity in optimal strategy plan and patients’ support care through treatment, the multidisciplinary team should weigh the risks and the benefits to patients in deciding whether to modify patients’ work-up and treatment approach. We cannot provide specific guidance on any other protocol of therapy – at this time, no clinical HNC-specific data on COVID-19 are available – but we can state that each decision requires an individualized risk/benefit assessment. The aim should be to protect HNC patients without compromising their oncologic outcome. It is paramount to stress open channels of communication between administrators, clinicians, patients and caregivers [6]. In order to assist shared decision-making, multidisciplinary team meetings should be promoted using web-platforms. A reasonable treatment strategy between anticancer therapy and epidemic prevention should be selected. It should be considered to: i) omit systemic therapy for patients ≥70 years or younger with co-morbidities, such as diabetes and cardiovascular diseases. On the one hand, the updated meta-analysis of chemotherapy in head and neck cancer (MACH-NC) did not show any survival benefit resulting from the addition of chemotherapy for elderly patients [3]. On the other hand, these relevant co-morbidities are linked to a higher risk of death in case of COVID-19 infection [7]. ii) omit cisplatin-based induction chemotherapy. A definitive benefit in overall survival with the incorporation of induction chemotherapy compared to standard (C)RT has not been proven in randomized studies [8]. iii) short overall treatment time. Definitive (C)RT should be limited to simultaneous integrated boost (SIB) techniques in the standard (5 fractions per week) or accelerated schedule (6 fractions per week), in order to achieve a 1-week reduction compared to sequential technique. SIB technique represents an optimum balance between tumor control and prevention of late toxicity excess [9]. iv) delay post-operative RT in patients with salivary gland tumors until 12 weeks after surgery. Time factor is not strictly linked to adverse effect in these cases [10]. v) develop an online surveillance plan. At present HNC patients deal with the double ordeals of disease and pandemic situation. Patients should be educated to properly identify those symptoms and signs that potentially signify a recurrence (increased local pain and difficulty in swallowing, unexplained weight loss and development of new lump in the head and neck region). For sure, patients should be informed regarding the Coronavirus symptoms (mainly fever, dyspnea and cough) and educated in proper hand washing and all other measures to limit viral transmission (avoid touching your eyes, nose and mouth; cover your nose and mouth with a tissue when you cough or sneeze; clean and disinfect high touch surfaces regularly; stop shaking hands or kissing as a greeting; reduce exposure to sick contacts and large crowds). Psychological counseling should be paid attention to through seeking alternative schemes. It must be appreciated that this document is an attempt to provide practical suggestions on how to define a reasonable treatment strategy and mitigate the COVID-19 impact on HNC patients under the current pandemic conditions. It is necessary to offer adequate individualized treatment recommendations based on both the epidemic situation and the patient's own condition. We significantly hope to help HNC patients to survive this difficult period.
  5 in total

1.  Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.

Authors:  Pierre Blanchard; Jean Bourhis; Benjamin Lacas; Marshall R Posner; Jan B Vermorken; Juan J Cruz Hernandez; Abderrahmane Bourredjem; Gilles Calais; Adriano Paccagnella; Ricardo Hitt; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

2.  The role of radiotherapy in the treatment of malignant salivary gland tumors.

Authors:  Chris H J Terhaard; Herman Lubsen; Coen R N Rasch; Peter C Levendag; Hans H A M Kaanders; Reineke E Tjho-Heslinga; Piet L A van Den Ende; Fred Burlage
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-01-01       Impact factor: 7.038

3.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.

Authors:  Jens Overgaard; Hanne Sand Hansen; Lena Specht; Marie Overgaard; Cai Grau; Elo Andersen; Jens Bentzen; Lars Bastholt; Olfred Hansen; Jørgen Johansen; Lisbeth Andersen; Jan F Evensen
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

4.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

Review 5.  COVID-19 and Italy: what next?

Authors:  Andrea Remuzzi; Giuseppe Remuzzi
Journal:  Lancet       Date:  2020-03-13       Impact factor: 79.321

  5 in total
  21 in total

Review 1.  Radiotherapy based management during Covid-19 pandemic - A systematic review of presented consensus and guidelines.

Authors:  Zahra Siavashpour; Neda Goharpey; Mosayyeb Mobasheri
Journal:  Crit Rev Oncol Hematol       Date:  2021-06-30       Impact factor: 6.312

Review 2.  Ethical framework for head and neck cancer care impacted by COVID-19.

Authors:  Andrew G Shuman; Bruce H Campbell
Journal:  Head Neck       Date:  2020-04-28       Impact factor: 3.147

3.  Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.

Authors:  Shao Hui Huang; Brian O'Sullivan; Jie Su; Jolie Ringash; Scott V Bratman; John Kim; Ali Hosni; Andrew Bayley; John Cho; Meredith Giuliani; Andrew Hope; Anna Spreafico; Aaron R Hansen; Lillian L Siu; Ralph Gilbert; Jonathan C Irish; David Goldstein; John de Almeida; Li Tong; Wei Xu; John Waldron
Journal:  Cancer       Date:  2020-06-01       Impact factor: 6.860

4.  Head and neck cancer cannot wait for this pandemic to end: Risks, challenges and perspectives of oral-maxillofacial surgeon during COVID-19.

Authors:  Valentino Valentini; Resi Pucci; Andrea Battisti; Andrea Cassoni
Journal:  Oral Oncol       Date:  2020-05-01       Impact factor: 5.337

Review 5.  Emergent and urgent otologic surgeries during the SARS-CoV-2 pandemic: a protocol and review of literature.

Authors:  Elise E Zhao; Joshua A Lee; Theodore R McRackan; Shaun A Nguyen; Ted A Meyer
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-05-30

6.  Managing locally advanced adenoid cystic carcinoma of the head and neck during the COVID-19 pandemic crisis: Is this the right time for particle therapy?

Authors:  Sara Ronchi; Barbara Vischioni; Maria Bonora; Amelia Barcellini; Laura D Locati; Paolo Castelnuovo; Piero Nicolai; Cesare Piazza; Mohssen Ansarin; Marco Benazzo; Ester Orlandi
Journal:  Oral Oncol       Date:  2020-05-14       Impact factor: 5.337

7.  Meeting the challenges imposed by COVID-19: Guidance document by the ESTRO Radiation TherapisT Committee (RTTC).

Authors:  Yat Tsang; Aileen Duffton; Michelle Leech; Maddalena Rossi; Philipp Scherer
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2020-05-22

Review 8.  Surge after the surge: Anticipating the increased volume and needs of patients with head and neck cancer after the peak in COVID-19.

Authors:  Ryan Bowman; Dana L Crosby; Arun Sharma
Journal:  Head Neck       Date:  2020-05-16       Impact factor: 3.147

9.  Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence.

Authors:  Elissar Moujaess; Hampig Raphael Kourie; Marwan Ghosn
Journal:  Crit Rev Oncol Hematol       Date:  2020-04-22       Impact factor: 6.625

10.  Have There Been any Changes in the Epidemiology and Etiology of Maxillofacial Trauma During the COVID-19 Pandemic? An Italian Multicenter Study.

Authors:  Giovanni Salzano; Giovanni Dell'Aversana Orabona; Giovanni Audino; Luigi Angelo Vaira; Lorenzo Trevisiol; Antonio D'Agostino; Resi Pucci; Andrea Battisti; Marco Cucurullo; Cristina Ciardiello; Ida Barca; Maria Giulia Cristofaro; Giacomo De Riu; Federico Biglioli; Valentino Valentini; Pier Francesco Nocini; Luigi Califano
Journal:  J Craniofac Surg       Date:  2021-06-01       Impact factor: 1.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.